← Back to calculator

Current regulator label

Tirzepatide

Tirzepatide

A plain-English reference on tirzepatide — what it is, its FDA-approved prescription status, how it is administered (once-weekly, subcutaneous), and key safety considerations. For dose-to-units math, use the tirzepatide dosage calculator.

Peptide Calculator X

Reconstitution / draw volume / syringe units / supply-chain

Arithmetic + reference toolNot medical advice
Inputs
Approved label
Product form
Target dose
Weight unit
Syringe barrel
Draw to
50units
0.5 mL5 mg/mL2.5 mg / dose
1 mL syringe - 100 u/mLFits
50 u050100 u
ARITHMETIC OK - VERIFY CLINICALLY

Arithmetic checks out. Confirm clinically, against the label, and against the actual vial before any use.

10 mg
4
0 mg
28 days
-
-

Independent check - dose mg / concentration mg/mL = volume. U-100 units = mL x 100.

Reconstitution planner

Reverse: pick a dose and the units you want it to read, then calculate diluent to add.

Reverse
Desired dose
1 mL
10 mg/mL
4
Formula and source context only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol. Do not use this tool to infer sterility, potency, purity, stability, compatibility, or an appropriate dose. Catalog and supply-chain data: finnrick.com/products - research date 2026-06-24.

Tirzepatide: reference record

Tirzepatide - regulatory status, route, frequency and published range
Regulatory statusFDA-approved prescription for labeled indications
RouteSubcutaneous
Dosing frequencyOnce weekly
Published range2.5–15 mg
Evidence basisCurrent regulator label
Common vial sizes10, 15, 30

Sources

What is Tirzepatide?

Tirzepatide is a synthetic peptide that activates both the GIP and GLP-1 receptors. It is the active ingredient in prescription products marketed for type 2 diabetes and for chronic weight management, and it is supplied by the manufacturer as a ready-to-use solution rather than as a powder you mix.

Is Tirzepatide FDA-approved?

Yes. Tirzepatide is an FDA-approved prescription medicine for its labeled indications, and the figures on this page come from the current FDA label. Approval covers specific licensed products; it does not extend to compounded or research-grade material sold under the same ingredient name.

How is Tirzepatide given?

Subcutaneously, once weekly, according to the product label. Commercial pens and vials arrive pre-mixed at a stated concentration, so no reconstitution is involved for the licensed product.

What are the known safety concerns with Tirzepatide?

It is prescription-only. Indication, contraindications, drug interactions and monitoring all sit with the prescriber and are outside the scope of an arithmetic tool. This page does not describe who should take it or at what amount.

Start 2.5 mg weekly; labeled maintenance 5, 10, or 15 mg weekly; max 15 mg

Commercial Zepbound is supplied pre-mixed in fixed-dose pens/vials. Use actual product concentration; do not invent a reconstitution.

Prescription-only; indication, titration, contraindications, interactions and monitoring are outside this calculator.

Supply-chain quality · Finnrick

Avg quality score

7

/10

Purity range

98.81

99.95

%

Qty divergence

±

49

%

Vendors · samples

176

·

2,188

Common vial sizes

10, 15, 30

mg

Test window

Dec 2024 - Jun 2026

Related calculators & comparisons

Browse all peptides →